Baylor Research Institute

Baylor Research Institute, a Dallas-based nonprofit hospital and research organization, operates primarily as a federal grant recipient in clinical and health services research, with secondary involvement as a subcontractor to academic and healthcare institution prime grantees. The organization holds no federal contracts but maintains an active federal grant portfolio anchored by the National Institutes of Health and the Department of Health and Human Services, competing predominantly in full-and-open settings.

Baylor Research Institute's capability footprint centers on clinical research translation, particularly interventions addressing traumatic brain injury, stroke recovery, diabetes prevention, and cancer detection. Representative prime grant work includes a $2.763 million Department of Defense Military Medical Research and Development award (CFDA 12.420) to conduct a randomized controlled trial of brief prolonged exposure therapy for PTSD prevention in Level I trauma center patients (awarded September 2023, running through September 2027); a $306,441 National Institute of Diabetes and Digestive and Kidney Diseases grant (CFDA 93.847) to evaluate rapid simultaneous therapy initiation in patients with concurrent chronic kidney disease and type 2 diabetes (awarded April 2026, running through March 2029); and a $250,000 National Institute on Disability, Independent Living, and Rehabilitation Research grant (CFDA 93.433) for a scale-up evaluation trial of the Group Lifestyle Balance diabetes prevention program adapted for traumatic brain injury populations (awarded September 2025, running through August 2028). A recent $186,457 National Cancer Institute Cancer Research Manpower award (CFDA 93.398) funds development and validation of a blood-based transcriptomic platform for glioblastoma detection and monitoring under a K22 career transition grant running September 2026 through August 2029, with work performed in Temple, Texas.

Customer concentration sits with HHS research funders: the National Institutes of Health accounts for 24 awards; the National Institute of Diabetes and Digestive and Kidney Diseases for 18 awards; the National Institute on Aging for 15 awards; and the National Cancer Institute for 11 awards. The Administration for Community Living funds 16 awards. These five customer bureaus account for 52% of recent awards. The Centers for Disease Control and Prevention Pittsburgh carries the largest combined potential value ($3 million across 3 awards), though the NIH portfolio dominates by count. Baylor Research Institute operates as prime on 93 awards (58% of recent activity), with 68 sub-awards (42%) routed through academic and healthcare institution prime grantees including Mayo Clinic Arizona, the University of Pennsylvania Trustees, University of Texas Southwestern Medical Center, Northwestern University, University of Washington, Baylor College of Medicine, and the Ohio State University. Sub-award work involves site-level principal investigator oversight, regulatory approvals, participant recruitment and enrollment, data collection, and manuscript preparation for multisite clinical trials spanning hepatocellular carcinoma prevention, Barrett's esophagus cancer risk stratification, spinal cord injury rehabilitation, Alzheimer's disease treatment, and dementia care outcomes.

Activity has grown from 5 awards in 2022 to 27 in 2024, moderating to 23 in 2025 and 11 in 2026 (year-to-date through September). Twelve awards reach ultimate completion within the next twenty-four months, representing recompete exposure. SCI-reported service contract invoicing captures $278 thousand in FY2022 across roughly 18 federal FTEs; the dataset is sparse and does not reflect the organization's total federal research funding or workforce, as most of Baylor Research Institute's federal footprint consists of research grants and sub-awards not reportable under Service Contract Inventory thresholds. The organization competes full-and-open in NIH grant mechanisms and NIDILRR research programs rather than restricted set-asides, and maintains minimal federal contract prime or IDIQ vehicle presence.